Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
暂无分享,去创建一个
S. Larson | N. Bander | D. Spratt | J. Osborne | D. Veach | W. Weber | P. Zanzonico | S. Cheal | E. K. Fung | B. Punzalan | V. Beylergil | S. Fareedy | Jawaria Amir | S. Chalasani | J. Amir
[1] J. Humm,et al. PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[2] R. Vessella,et al. Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts , 2015, The Prostate.
[3] N. Bander,et al. Microtubule inhibitor-based antibody–drug conjugates for cancer therapy , 2014, OncoTargets and therapy.
[4] Serge K. Lyashchenko,et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[5] W. Olson,et al. Antibody-drug conjugates targeting prostate-specific membrane antigen. , 2014, Frontiers in bioscience.
[6] S. Larson,et al. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[7] Stanley J. Goldsmith,et al. Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.
[8] Ralph Weissleder,et al. Quantitating Antibody Uptake In Vivo: Conditional Dependence on Antigen Expression Levels , 2011, Molecular Imaging and Biology.
[9] S. Larson,et al. 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo , 2010, The Journal of Nuclear Medicine.
[10] G. Adams,et al. Affinity and avidity in antibody-based tumor targeting. , 2009, Cancer biotherapy & radiopharmaceuticals.
[11] Sung-Cheng Huang,et al. Estimation of the 18F-FDG Input Function in Mice by Use of Dynamic Small-Animal PET and Minimal Blood Sample Data , 2007, Journal of Nuclear Medicine.
[12] S. Vallabhajosula,et al. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice , 2004, The Prostate.
[13] William C. Olson,et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[14] R. Boellaard,et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] W. Oyen,et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] N. Bander,et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.
[17] V. Reuter,et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.
[18] F Regan,et al. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. , 1998, Clinical nuclear medicine.
[19] N. Bander,et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.
[20] N. Bander,et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.
[21] M. Goris,et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] I. Bernstein,et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.
[23] George L. Wright,et al. Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.
[24] G. Griffiths,et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] G. Griffiths,et al. Processing of antibody‐radioisotope conjugates after binding to the surface of tumor cells , 1994, Cancer.
[26] S. Anderson,et al. Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores. , 1990, Cancer research.
[27] G. Murphy,et al. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.